Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Blueprint Medicines
Blueprint Medicines
(BPMC)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ayvakit
Avapritinib
2020-01-09
2034
Gastrointestinal stromal tumors
Ayvakyt
Avapritinib
2020-09-24
2034
Gastrointestinal stromal tumors
Gavreto
Pralsetinib
2020-09-04
2036-2039
Non-small-cell lung carcinoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Avapritinib
systemic mastocytosis
,
mast-cell leukemia
,
hematologic neoplasms
,
neoplasms
,
gastrointestinal stromal tumors
Pralsetinib
non-small-cell lung carcinoma
,
carcinoma
,
neoplasms
,
head and neck neoplasms
,
lung neoplasms
,
respiratory tract diseases
,
germ cell and embryonal neoplasms
,
small cell lung carcinoma
,
lung diseases
,
respiratory tract neoplasms
,
bronchogenic carcinoma
,
thoracic neoplasms
,
bronchial diseases
,
neoplasms by histologic type
,
neoplasms by site
,
nerve tissue neoplasms
,
papillary thyroid cancer
,
medullary thyroid cancer
Sugemalimab
hepatocellular carcinoma
,
liver neoplasms
Sbrt
non-small-cell lung carcinoma
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use